feedback

Activity Details

Free CME
1 AMA PRA Category 1 Credit(s)
Released: June 18, 2020
Expires: April 18, 2021
60 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Target Audience

The target audience for this activity is gynecologic oncologists, medical oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies.

Learning Objectives

After participating in this activity, participants should be better able to:

  • Assess the efficacy and safety of PARP inhibitors or their combinations in the maintenance and treatment setting for the management of patients with ovarian cancer
  • Evaluate the various genetic testing platforms and their utility in identifying appropriate patients for platinum-based therapy and PARP inhibitor therapy
  • Develop strategies for the optimal utilization of PARP inhibitors when managing patients with ovarian cancer
  • Review novel agents that are under investigation for the treatment of platinum-resistant ovarian cancer

Activity Description

This activity will provide expert guidance regarding the use of currently-available therapies and companion diagnostics and will help clinicians plan for the optimal integration of new indications and combinations into practice when they become available.

Statement of Educational Need

Considering the volume of research regarding the use of PARP inhibitors for patients with ovarian cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Thus, clinicians treating patients with ovarian cancer need expert guidance to evaluate emerging scientific and clinical data, use existing PARP inhibitors safely and effectively, and plan strategies to appropriately integrate new indications and combinations into practice when they become available, in consideration of patient needs and preferences.

Agenda

  • Currently Available Systemic and Maintenance Therapies and Emerging Combinations for the Treatment of Ovarian Cancer
  • Integrating Genetic Testing Into Clinical Practice
  • Real-World Use of Poly ADP Ribose Polymerase Inhibitors (PARPi): Case-Based Discussion
  • Summary

 

Faculty

Thomas Herzog, MD
Deputy Director, University of Cincinnati Cancer Institute
Paul & Carolyn Flory Professor, Vice-Chair of Quality & Safety
Department of Obstetrics & Gynecology
University of Cincinnati
Cincinnati, Ohio

Disclosures
Advisory Boards: AstraZeneca, Caris Life Sciences, Clovis Oncology, F. Hoffman-La Roche, Tesaro, Inc.


Conflict of Interest Policy/Disclosure Statement

Faculty and Planning Committee Disclosures

As a provider accredited by ACCME, the UNMC Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.

The faculty and planning committee members for this activity have no conflicts to disclose with the exception of those listed on the following presenter slide. All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

Continuing Education

The University of Nebraska Medical Center (UNMC) Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The UNMC Center for Continuing Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of the UNMC Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.

Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.

Materials will be available online through April 18, 2021.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca, Clovis Oncology, and Tesaro, a GSK Company.

Disclaimer Statement/Disclosure of Unlabeled Use

UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend.

Contact Information for Questions About the Activity

cme@bioascend.com

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.